Wolverine Asset Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Wolverine Asset Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-399	Closed	-$7.93K	–	1955
2023 Q2	$7.93K	Hold	399	–	–	﹤0.01%	1417
2023 Q1	$6.83K	Hold	399	–	–	﹤0.01%	1504
2022 Q4	$7.81K	Buy	+399	New	+$7.35K	﹤0.01%	1674

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Wolverine Asset Management's RCKT Position: Q3 2023 in Review

Wolverine Asset Management sold out of Rocket Pharmaceuticals (RCKT) in Q3 2023, closing a stake of 399 shares — an estimated $7.93K sold.

Wolverine Asset Management first reported a position in RCKT in Q4 2022 and held it in 3 quarters. The position peaked at $7.93K in Q2 2023. 175 funds tracked by Wall St. Rank hold RCKT as of Q3 2023.

Wolverine Asset Management reported no remaining Rocket Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Wolverine Asset Management sold 399 Rocket Pharmaceuticals shares in Q3 2023, an estimated $7.93K.
Wolverine Asset Management first reported a position in Rocket Pharmaceuticals in Q4 2022 and held it in 3 quarters.
Wolverine Asset Management's Rocket Pharmaceuticals position peaked at $7.93K in Q2 2023.
175 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2023.

Based on Wolverine Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.